Fujita K
Cancer. 1987 Jun 15;59(12):2027-30. doi: 10.1002/1097-0142(19870615)59:12<2027::aid-cncr2820591210>3.0.co;2-n.
Seventy-eight patients with superficial bladder cancer were entered into a randomized study. A streptococcal preparation, OK-432, was injected into bladder cancers before transurethral resection and instilled into the bladder for 6 months after resection to reduce the recurrence. The control group were only transurethrally resected, as usual. The recurrence rate for patients with primary disease was 3.6 in 100 months for the OK-432 group and 9.1 in 100 months for the control group (P less than 0.05). In the control group, multiple, large, sessile, and high-grade tumors had high recurrence rates. But in the OK-432 group, overall recurrence rates were low in both high-risk and low-risk patients. Supplementary immunotherapy is especially effective and is recommended in high-risk patients.
78例浅表性膀胱癌患者进入一项随机研究。一种链球菌制剂OK-432，在经尿道切除术前注入膀胱癌中，并在切除术后注入膀胱6个月以降低复发率。对照组像往常一样仅接受经尿道切除术。OK-432组原发性疾病患者100个月的复发率为3.6，对照组为9.1（P<0.05）。在对照组中，多发、大的、无蒂的和高级别肿瘤有较高的复发率。但在OK-432组中，高风险和低风险患者的总体复发率均较低。辅助免疫疗法特别有效，推荐用于高风险患者。
